Droloxifene is a nonsteroidal selective estrogen receptor modulator belonging to the triphenylethylene class, primarily indicated for the treatment of breast cancer in postmenopausal women. By selectively… Read more
Droloxifene is a nonsteroidal selective estrogen receptor modulator belonging to the triphenylethylene class, primarily indicated for the treatment of breast cancer in postmenopausal women. By selectively binding to estrogen receptors, this compound inhibits tumor growth while helping to mitigate bone loss associated with estrogen deprivation. The pharmaceutical reference standards, metabolites, and stable isotope labelled compounds in this category are critical for analytical testing and quality control within pharmaceutical laboratories. Scientists utilize these materials for accurate impurity profiling, rigorous method validation, and the precise quantification of the active pharmaceutical ingredient. By providing high-quality reference materials, including deuterated derivatives like N-Desmethyl Droloxifene-d5, laboratories can ensure the sensitivity and reliability of their analytical assays during both drug development and routine manufacturing.